Ann Hanham - Net Worth and Insider Trading
Ann Hanham Net Worth
The estimated net worth of Ann Hanham is at least $17 Million dollars as of 2024-04-16. Ann Hanham is the Director of Endocyte Inc and owns about 705,435 shares of Endocyte Inc (ECYT) stock worth over $17 Million. Ann Hanham is also the Director of SCYNEXIS Inc and owns about 3,622 shares of SCYNEXIS Inc (SCYX) stock worth over $5,107. Details can be seen in Ann Hanham's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ann Hanham has not made any transactions after 2020-12-21 and currently still holds the listed stock(s).
Transaction Summary of Ann Hanham
Ann Hanham Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ann Hanham owns 4 companies in total, including HTG Molecular Diagnostics Inc (HTGMQ) , SCYNEXIS Inc (SCYX) , and Endocyte Inc (ECYT) among others .
Click here to see the complete history of Ann Hanham’s form 4 insider trades.
Insider Ownership Summary of Ann Hanham
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HTGMQ | HTG Molecular Diagnostics Inc | 2016-08-25 | director |
| SCYX | SCYNEXIS Inc | 2023-06-15 | director |
| ECYT | Endocyte Inc | 2017-05-04 | director |
| CBIO | Catalyst Biosciences Inc | 2006-04-11 | director |
Ann Hanham Latest Holdings Summary
Ann Hanham currently owns a total of 2 stocks. Among these stocks, Ann Hanham owns 705,435 shares of Endocyte Inc (ECYT) as of May 28, 2013, with a value of $17 Million and a weighting of 99.97%. Ann Hanham also owns 3,622 shares of SCYNEXIS Inc (SCYX) as of December 21, 2020, with a value of $5,107 and a weighting of 0.03%.
Latest Holdings of Ann Hanham
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ECYT | Endocyte Inc | 2013-05-28 | 705,435 | 23.99 | 16,923,386 |
| SCYX | SCYNEXIS Inc | 2020-12-21 | 3,622 | 1.41 | 5,107 |
Holding Weightings of Ann Hanham
Ann Hanham Form 4 Trading Tracker
According to the SEC Form 4 filings, Ann Hanham has made a total of 0 transactions in Endocyte Inc (ECYT) over the past 5 years. The most-recent trade in Endocyte Inc is the sale of 9,900 shares on May 28, 2013, which brought Ann Hanham around $139,590.
According to the SEC Form 4 filings, Ann Hanham has made a total of 1 transactions in SCYNEXIS Inc (SCYX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in SCYNEXIS Inc is the acquisition of 3,200 shares on December 21, 2020, which cost Ann Hanham around $20,000.
Insider Trading History of Ann Hanham
- 1
Ann Hanham Trading Performance
GuruFocus tracks the stock performance after each of Ann Hanham's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ann Hanham is 10.05%. GuruFocus also compares Ann Hanham's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ann Hanham within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ann Hanham's insider trading performs compared to the benchmark.
Performance of Ann Hanham
Average Relative Return
-14.86%
Outperforming Transactions
50%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | -7.67 | 10.05 | 14.29 | -14.86 | -37.2 | -30.01 |
| Relative Return to S&P 500(%) | -8.54 | 5.14 | 4.18 | -35.53 | -45.47 | -39.65 |
Ann Hanham Ownership Network
Ownership Network List of Ann Hanham
Ownership Network Relation of Ann Hanham
Ann Hanham Owned Company Details
What does HTG Molecular Diagnostics Inc do?
Who are the key executives at HTG Molecular Diagnostics Inc?
Ann Hanham is the director of HTG Molecular Diagnostics Inc. Other key executives at HTG Molecular Diagnostics Inc include Senior VP of Therapeutics Stephen Barat , 10 percent owner L5 Capital Inc. , and SVP/Chief Commercial Officer Byron Lawson .
HTG Molecular Diagnostics Inc (HTGMQ) Insider Trades Summary
Over the past 18 months, Ann Hanham made no insider transaction in HTG Molecular Diagnostics Inc (HTGMQ). Other recent insider transactions involving HTG Molecular Diagnostics Inc (HTGMQ) include a net sale of 888 shares made by Stephen Barat ,
In summary, during the past 3 months, insiders sold 0 shares of HTG Molecular Diagnostics Inc (HTGMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 888 shares of HTG Molecular Diagnostics Inc (HTGMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 888 shares.
HTG Molecular Diagnostics Inc (HTGMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
HTG Molecular Diagnostics Inc Insider Transactions
Ann Hanham Mailing Address
Above is the net worth, insider trading, and ownership report for Ann Hanham. You might contact Ann Hanham via mailing address: One Embracadero Ctr, Ste 2700, San Francisco Ca 94111.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
